Tetra Bio-Pharma Discusses Their 2020 Growth Strategy with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 21, 2020) - The Stock Day Podcast welcomed Tetra Bio-Pharma (TSXV: TBP) (OTCQB: TBPMF), a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Chief Scientist and Founder of the Company, Dr. Guy Chamberland, joined Stock Day host Everett Jolly.
Jolly began the interview by noting that the Company recently received a favorable Letter of Advice from the FDA for QIXLEEF™, an advanced cancer pain solution under the Company's drug development program for chronic pain. Dr. Chamberland expanded on the Company's focus on developing chronic pain solutions using biopharmaceuticals infused with cannabinoids and other plant-based compounds. Dr. Chamberland then shared that while there have been many that were surprised by the FDA's decision to support the development of such pharmaceuticals, he saw it as a natural progression of their pipeline. "Deliver the science and show it is safe, and the FDA will grant you the approval," said Dr. Chamberland.
"Why do you think the FDA is really supportive of dry flower-bud prescription drugs?" asked Jolly. Dr. Chamberland shared that it is important for regulators to obtain and review as much data as possible for drugs entering the marketplace, and explained that the FDA is supportive of new drugs as long as there is science and data behind them. "It's a question of the risk versus benefit, but if you don't do the science, you'll never be able to address that," said Dr. Chamberland.
Jolly then inquired about the Company's recent announcement regarding an agreement in Portugal. "We're now up to two pharamaceutical companies - the Portuguese one is actually one of the oldest pharmaceutical companies," said Dr. Chamberland. "They basically agreed that after we finish the trials they are going to be a company willing to sell and distribute the drugs to patients in Portugal," explained Dr. Chamberland, adding that the Company has also established a similar partnership in Mexico. "We're starting to see pharmaceutical companies position themselves to want to sell and distribute our product," he added.
The conversation then turned to CBD and GRAS status. "One of the problems is that there is not enough science. So, CBD has been isolated as an ingredient that we know from phytopharmacology that often when we isolate ingredients we discover things we didn't know about it," explained Dr. Chamberland. "One of the things we are discovering is that in relatively high doses that CBD can cause liver injury," said Dr. Chamberland. "The rest of the toxicology, if you look at what was reviewed by the FDA, is relatively good. So, overall you could say CBD is relatively safe, but CBD is also accumulating in the blood if you take it every day, so a regulator needs data," explained Dr. Chamberland.
"The consumers want the products faster than the industry can deliver the science. In my opinion, that's going to be one of the challenges in 2020," said Dr. Chamberland when discussing the importance of having regulators establish a safe and appropriate daily dose for CBD products and pharmaceuticals.
Dr. Chamberland closed the interview by sharing his excitement for the Company's transformation in 2020. "We have to really become a pharmaceutical company in a sense, and that's going to be the year Tetra transforms," shared Dr. Chamberland, noting that the Company plans to follow an aggressive growth strategy to achieve its goals.
To hear Guy Chamberland's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7483841-tetra-bio-pharma-discusses-their-2020-growth-strategy-with-the-stock-day-podcast
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSXV: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant- based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward- looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on
forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.:
LifeSci Advisors LLC
LifeSci Public Relations
514-288-8500 ext. 226
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
Stock Day Media
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/51692